STAT10h
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
KELO6h
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...
Novo Nordisk's experimental weight loss pill has some concerning side effects
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...